Dear Colleagues,

Cancer is the leading cause of death worldwide and shortens life expectancy. The current pathological staging of tumors is of great value in predicting prognosis, but given the high morbidity and mortality of cancer, there is an urgent need for novel biomarkers that can predict prognosis against tumors and immunotherapy. Over the past decades, multiple tumor biomarkers have been validated and are now widely used in the clinic and proven to be effective. In recent years, with the emergence of iron death, copper death and disulfide death, new insights into the impact of metabolic genes on tumorigenesis, progression and treatment have been achieved and are considered as new directions for tumor therapy. The development of high-throughput sequencing technologies in proteomics and genomics has made it possible to study metabolic gene markers. The identification of metabolic gene markers is crucial for the development of therapeutic targets for precision immuno-oncology, which will also have a profound impact in the field of personalized medicine. The aim of this special issue is to bring together original research and review articles with a focus on tumor prognosis, identification of novel metabolic genes for immunotherapy, with an emphasis on immunotherapy.

Dr. Jian Song and Dr. Xueli Zhang
Guest Editors